joint ventur icon brand
gsk separ
gsk commit keep dividend stabl
close
gsk pfe consum jv repres world-lead
gsk hold announc combin consum health
ch busi joint-ventur gsk/pfe ownership
gsk-pfe consum health busi pro-forma sale
make joint-ventur industri leader multipl household
brand name gsk/pfe expect transact close conting
sharehold anti-trust approv importantli gsk expect
separ jv demerg applaud gsk effort
exit consum healthcar focu pharma vaccin gsk-pfe jv
make strateg sens parti allow singularli focu
effort respect pharma vaccin busi recent lunch
pfe ceo analyst remind compani look
announc pfe chc franchis year-end see note titl
thought lunch pfe incom ceo head in-lin
gsk initi report see note titl growth outlook
eu peer group initi hold rate price
gsk expect pay dividend confirm
maintain stabl dividend reiter gsk-u adr
base usd/gbp spot rate assum gsk-gb trade ep
group average support dcf downsid risk includ dividend
cut hiv price concern hh propos advair gx competit pipelin
setback upsid could come oncolog success viiv uptak
vaccin franchis shingrix
ch spin allow much need focu pharma vaccin
overal gsk expect jv achiev adjust oper margin
mid-to-high stand-alon
busi gsk report sale adjust oper profit
adj om consum health report sale
adj oper profit adj om
gsk consum busi report sale adjust oper
profit oper margin see high probabl
transact close gsk expect transact accret
total earn second full year follow close accret
adjust earn free cash flow first full year close
gsk-pfe ch jv target adjust oper margin mid-to-high
recal june gsk complet
buy-out novarti nv rate stake consum health joint
ventur transact announc march gsk divest
care-india gsk sell equiti stake divestitur unilev ulvr-gb rate
think consum health busi experienc signific price pressur us e-
commerc growth contribut consolid
gsk-pfe consum gener synergi
gsk/pfe jv creat world-lead busi consum healthcar offer signific
opportun growth cost synergi gsk target cost synergi save
jv enabl cash/non-cash charg jv creat
lead consum franchis pain global rank vitamin supplement respiratori
digest health therapeut oral health skin health gsk lead
brand includ sensodyn voltaren panadol pfe top brand advil centrum
caltrat jv largest global market share over-the-counter market vs player
posit categori leader key geographi us share latin
asia jv expect creat effici scalabl organ
global footprint complementari product offer
busi year gsk clinical/regulatori front
see gener competit advair immin rate readi launch
pend fda approv follow novemb european chmp posit opinion tivicay
label updat gemini data expect european commiss approv dolutegravir
lamivudin late januari viiv healthcar plan present full atla flair result
cabotegravir rilviprin upcom confer retrovirus opportunist infect
march seattl wa gsk plan file us regulatori base atla flair
studi anticip gsk share two-year updat data gemini studi dolutegravir
lamivudin gsk expect secur fda approv dolutegravir lamivudin base
gemini data gsk expect tesaro tsro hold peter lawson acquisit transact
close pend regulatori approv gsk expect proof-of-concept data
hbv aso gsk also plan launch auto-injector version
nucala at-hom use gsk plan share proof-of-concept data
inh bet inh matur inhibitor inhibitor
page
valuat risk
although gsk trade slight discount price-to-earnings pe basi eu pharma group
think modest turn premium justifi compani aim grow oncolog hiv
vaccin franchis gsk-u adr base current usd/gbp spot rate assum
gsk-gb trade ep premium vs grp average support dcf analysi
also support dcf analysi yield fair valu estim gsk
base free cash flow estim termin growth rate weight averag
cost capit wacc sensit analysi show chang termin growth
rate wacc assumpt yield chang fair valu respect
grow concern around dividend cut gsk attract dividend yield well averag eu
major pharma group expect gsk priorit use free cash flow maintain
dividend current level expect gsk concentr pay debt long-term
meaning increas dividend announc
increas hiv price concern view increas price concern around hiv drug notabl
risk gsk viiv busi short long-term
oncolog becom signific growth driver although see gsk attempt re-establish
oncolog franchis prematur stage pipelin read-out tesaro acquisit could
possibl improv growth franchis mid-to-long term
viiv success pivot two-drug regimen viiv overal strategi simplifi hiv treatment
regimen pursu two-drug combo could help gsk gain signific foothold hiv market
three-drug combin standard care hiv patient repres sever
disadvantag patient physician provid could address two-drug regimen
bearish bullish risk
clinic risk pipelin model assum gsk gener nominal/
risk-adjust peak sale pipelin product could meaning upsid
downsid our/street sales/ep estim gsk pipelin opportun commerci
commerci come fall expect
regulatori risk gsk could gener posit clinic result howev guarante
global regul approv import nme/nilex opportun gsk pipelin
compani mention note
novarti nv rate
unilev ulvr-gb rate
rate
john bori herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
page
analyst compens base upon stock price perform qualiti analysi commun skill
overal revenu profit firm includ invest bank revenu
matter polici practic firm prohibit offer favor research specif
research rate specif target price consider induc receipt busi
compens addit associ person prepar research report prohibit own
secur subject compani
rate price target histori glaxosmithklin plc gsk-u
rate price target histori pfizer inc pfe-u
creat bluematrix
creat bluematrix
strh rate system equiti secur
dissemin research
suntrust robinson humphrey strh seek make reason effort provid research report
simultan elig client report avail publish restrict access area
websit elig client request password institut investor corpor
member press may also receiv research via third parti vendor includ thomson reuter
bloomberg factset capit iq addit distribut may done sale personnel via
email fax electron mean regular mail
access third parti vendor research websit http //suntrustlibrari bluematrix com/client/
pleas email research depart
contact strh sale repres
rate system effect oct
strh rate equiti secur
rate rel broader market gener next month unless
page
buy stock total return expect outperform relev benchmark
hold stock total return expect perform line relev benchmark
next month unless otherwis indic
sell stock total return expect under-perform relev benchmark
next month unless otherwis indic
rate nr strh invest rate opinion stock
coverag suspend cs indic strh rate and/or target price temporarili
suspend due applic regul and/or strh manag discret previous publish
rate target price reli upon
strh analyst price target stock cover unless otherwis indic price
target repres analyst expect stock trade next month unless
otherwis indic analyst believ insuffici valuat driver and/or invest
catalyst deriv posit neg invest view may elect approv strh
research manag assign target price likewis certain stock trade may
exhibit volatil wherebi assign price target would unhelp make invest decis
research manag approv analyst may refrain assign target sub-
legend rate price target histori chart
prior rate system oct
design base total return within period
buy total return low-beta secur
reduc total return neg low beta secur
neutral total return within bound
nr rate strh provid equiti research coverag
total return price appreci dividend price target within period unless
otherwis note beta defin secur averag beta less use bloomberg
suntrust robinson humphrey rate distribut
